Poly(lactic-co-glycolic acid) nanoparticles and microparticles for peptide delivery: release mechanisms and controlling factors: Review paper

Mohammadmahdi Eshaghi; Marzieh   Dehghani; Azam Abedi; Mehrdad Moosazadeh Moghaddam; Ramezan Ali  Taheri

doi:10.5599/admet.3091

Authors

Mohammadmahdi Eshaghi Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-1612-6989
Marzieh Dehghani Department of Biophysics, College of Biological Sciences, Tarbiat Modares University, Tehran, Iran https://orcid.org/0009-0001-5121-7037
Azam Abedi Tissue Engineering and Regenerative Medicine Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-2750-1203
Mehrdad Moosazadeh Moghadam Tissue Engineering and Regenerative Medicine Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0002-4645-8661
Ramezan Ali Taheri Nanobiotechnology Research Center, New Health Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran https://orcid.org/0000-0003-1394-6412

DOI:

https://doi.org/10.5599/admet.3091

Keywords:

Poly(lactic-co-glycolic acid), drug delivery, particle, nanomaterial

Abstract

Background and purpose: Therapeutic peptides offer high potency but are limited by rapid degradation, poor bioavailability, and the need for frequent dosing. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles and microparticles are effective carriers capable of protecting peptides and enabling controlled release. This review summarizes the mechanisms governing peptide release from PLGA particles and identifies formulation factors critical for optimizing therapeutic performance. Approach: A comprehensive analysis of polymer characteristics, particle design parameters, peptide physicochemical properties, and formulation strategies was conducted using data from recent studies. Release mechanisms, including diffusion, polymer degradation, and erosion, were examined alongside manufacturing methods. The review also evaluates clinical PLGA-based peptide products to highlight translational relevance. Key results: Peptide release profiles are strongly influenced by PLGA molecular weight, lactide:glycolide ratio, particle size, end-group chemistry, drug loading, and excipients. Lower polymer molecular weight, higher glycolide content, and smaller particle dimensions accelerate release, whereas cationic peptides experience electrostatic retention within degrading matrices. Additives such as PEG, magnesium salts, and chitosan coatings effectively modulate burst release and stability. PLGA systems typically display triphasic release profiles governed by diffusion and erosion. Several PLGA microparticle-based peptide depots have achieved clinical success, although no nanoparticle-based products have yet reached the market due to manufacturing and regulatory challenges. Conclusion: PLGA nano- and microparticles provide versatile, tuneable platforms for sustained peptide delivery. Understanding the interplay between polymer properties, particle architecture, and peptide characteristics is essential for designing next-generation long-acting formulations with improved efficacy and clinical translation.

Downloads

Download data is not yet available.

References

[1] D.J. Hines, D.L. Kaplan. Poly (lactic-co-glycolic) acid− controlled-release systems: experimental and modeling insights. Critical Reviews™ in Therapeutic Drug Carrier Systems 30(2013) 257-276. https://doi.org/10.1615/critrevtherdrugcarriersyst.2013006475 DOI: https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2013006475

[2] H.K.Makadia,S.J.Siegel. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3(2011)1377-1397. https://doi.org/10.3390/polym3031377 DOI: https://doi.org/10.3390/polym3031377

[3] H. Bhardwaj, R.K. Jangde. Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications. Next Nanotechnology 2(2023) 100013. https://doi.org/10.1016/j.nxnano.2023.100013 DOI: https://doi.org/10.1016/j.nxnano.2023.100013

[4] M.B. Giles, J.K. Hong, Y. Liu, J. Tang, T. Li, A. Beig, A. Schwendeman, S.P. Schwendeman. Efficient aqueous remote loading of peptides in poly (lactic-co-glycolic acid). Nature Communications 13 (2022) 3282. https://doi.org/10.1038/s41467-022-30813-7 DOI: https://doi.org/10.1038/s41467-022-30813-7

[5] Y. Su, B. Zhang, R. Sun, W. Liu, Q. Zhu, X. Zhang, R. Wang, C. Chen. PLGA-based biodegradable microspheres in drug delivery: recent advances in researchapplication. Drug Delivery 28(2021)1397-1418. https://doi.org/10.1080/10717544.2021.1938756 DOI: https://doi.org/10.1080/10717544.2021.1938756

[6] M. Pourmadadi,M.M. Eshaghi, S. Ostovar, Z. Mohammadi, R.K. Sharma, A.C. Paiva-Santos, E. Rahmani, A. Rahdar, S. Pandey. Innovative nanomaterials for cancer diagnosis, imaging, and therapy: Drug delivery applications. Journal of Drug Delivery Science and Technology 82(2023)104357. https://doi.org/10.1016/j.jddst.2023.104357 DOI: https://doi.org/10.1016/j.jddst.2023.104357

[7] P.W. Lee, J.K. Pokorski. Poly (lactic‐co‐glycolic acid) devices: Production and applications for sustained protein delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 10(2018)1516. https://doi.org/10.1002/wnan.1516 DOI: https://doi.org/10.1002/wnan.1516

[8] X. Luan, R. Bodmeier. Influence of the poly (lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. Journal of Controlled Release 110(2006) 266-272. https://doi.org/10.1016/j.jconrel.2005.10.005 DOI: https://doi.org/10.1016/j.jconrel.2005.10.005

[9] J. Yang, H. Zeng, Y. Luo, Y. Chen, M. Wang, C. Wu, P. Hu. Recent Applications of PLGA in drug delivery systems. Polymers 16(2024)2606. https://doi.org/10.3390/polym16182606 DOI: https://doi.org/10.3390/polym16182606

[10] M. Ochi, B. Wan, Q. Bao, D.J. Burgess. Influence of PLGA molecular weight distribution on leuprolide release from microspheres. International Journal of Pharmaceutics 599(2021)120450. https://doi.org/10.1016/j.ijpharm.2021.120450 DOI: https://doi.org/10.1016/j.ijpharm.2021.120450

[11] H. Kranz, R. Bodmeier. A novel in situ forming drug delivery system for controlled parenteral drug delivery. International journal of Pharmaceutics (2007)107-114. https://doi.org/10.1016/j.ijpharm.2006.09.033 DOI: https://doi.org/10.1016/j.ijpharm.2006.09.033

[12] P.G. Schmidt, K.M. Campbell, K.D. Hinds, G.P. Cook. PEGylated bioactive 332molecules in biodegradable polymer microparticles. Expert Opinion on Biological Therapy 7(2007)1427-1436. https://doi.org/10.1517/14712598.7.9.1427 DOI: https://doi.org/10.1517/14712598.7.9.1427

[13] S.C. Balmert, A.C. Zmolek, A.J. Glowacki, T.D. Knab, S.N. Rothstein, J.M. Wokpetah, M.V. Fedorchak, S.R. Little. Positive charge of “sticky” peptides and proteins impedes release from negatively charged PLGA matrices. Journal of Materials Chemistry B 3(2015)4723-4734. https://doi.org/10.1039/C5TB00515A DOI: https://doi.org/10.1039/C5TB00515A

[14] M.H. Zada, Y. Rottenberg, A.J. Domb. Peptide loaded polymeric nanoparticles by non-aqueous nanoprecipitation. Journal of Colloid and Interface Science 622(2022)904-913. https://doi.org/10.1016/j.jcis.2022.05.007 DOI: https://doi.org/10.1016/j.jcis.2022.05.007

[15] H.B. Ravivarapu, K. Burton, P.P. DeLuca. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. European Journal of Pharmaceutics and Biopharmaceutics 50(2000)263-270. https://doi.org/10.1016/S0939-6411(00)00099-0 DOI: https://doi.org/10.1016/S0939-6411(00)00099-0

[16] J. Kim, R.L. e Silva, R.B. Shmueli, A.C. Mirando, S.Y. Tzeng, N.B. Pandey, E. Ben-Akiva, A.S. Popel, P.A. Campochiaro, J.J. Green. Anisotropic poly (lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization. Acta Biomaterialia 97(2019)451-460. https://doi.org/10.1016/j.actbio.2019.07.054 DOI: https://doi.org/10.1016/j.actbio.2019.07.054

[17] A. Vlachopoulos, G. Karlioti, E. Balla, V. Daniilidis, T. Kalamas, M. Stefanidou, N.D. Bikiaris, E. Christodoulou, I. Koumentakou, E. Karavas, D.N. Bikiaris. Poly (lactic acid)-based microparticles for drug delivery applications: An overview of recent advances. Pharmaceutics 14(2022)359. https://doi.org/10.3390/pharmaceutics14020359 DOI: https://doi.org/10.3390/pharmaceutics14020359

[18] M. Allahyari, E. Mohit. Peptide/protein vaccine delivery system based on PLGA particles. Human Vaccines & Immunotherapeutics 12(2016)806-828. https://doi.org/10.1080/21645515.2015.1102804 DOI: https://doi.org/10.1080/21645515.2015.1102804

[19] J. Yoo, Y.Y. Won. Phenomenology of the initial burst release of drugs from PLGA microparticles. ACS Biomaterials Science & Engineering 6(2020)6053-6062. https://doi.org/10.1021/acsbiomaterials.0c01228 DOI: https://doi.org/10.1021/acsbiomaterials.0c01228

[20] K.T. Santhosh, A. Alizadeh, S. Karimi-Abdolrezaee. Design and optimization of PLGA microparticles for controlled and local delivery of Neuregulin-1 in traumatic spinal cord injury. Journal of Controlled Release 261(2017)147-162. https://doi.org/10.1016/j.jconrel.2017.06.030 DOI: https://doi.org/10.1016/j.jconrel.2017.06.030

[21] C. De Soricellis, C. Laigle, L. Spinelli, M.C. Monti, C. Amante, P. Russo, R.P. Aquino, P. Rousselle, G. Lollo, P. Del Gaudio. Lipidized LL37-loaded PLGA nanocarriers: Bioengineered peptide delivery systems for enhanced wound healing. International Journal of Pharmaceutics 677 (2025) 125668. https://doi.org/10.1016/j.ijpharm.2025.125668 DOI: https://doi.org/10.1016/j.ijpharm.2025.125668

[22] F.Y. Han, W. Xu, V. Kumar, C.S. Cui, X. Li, X. Jiang, T.M. Woodruff, A.K. Whittaker, M.T. Smith. Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. Pharmaceutics 13(2021)1505. https://doi.org/10.3390/pharmaceutics13091505 DOI: https://doi.org/10.3390/pharmaceutics13091505

[23] H.A.D.M. Abu-Awwad, L. Thiagarajan, J.E. Dixon. Controlled release of GAG-binding enhanced transduction (GET) peptides for sustained and highly efficient intracellular delivery. Acta Biomaterialia 57(2017)225-237. https://doi.org/10.1016/j.actbio.2017.04.028 DOI: https://doi.org/10.1016/j.actbio.2017.04.028

[24] A.G. Ding, S.P. Schwendeman. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharmaceutical Research 25(2008)2041-2052. https://doi.org/10.1007/s11095-008-9594-3 DOI: https://doi.org/10.1007/s11095-008-9594-3

[25] R.C. Mundargi, V.R. Babu, V.Rangaswamy, P. Patel, and T.M. Aminabhavi. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. Journal of Controlled Release 125(2008)193-209. https://doi.org/10.1016/j.jconrel.2007.09.013 DOI: https://doi.org/10.1016/j.jconrel.2007.09.013

[26] A.F. Soares, R.D.A. Carvalho, F. Veiga. Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomedicine 2(2007)183-202. https://doi.org/10.2217/17435889.2.2.183 DOI: https://doi.org/10.2217/17435889.2.2.183

[27] T. Akagi, M. Baba, M. Akashi. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Polymers in Nanomedicine247 (2012) 31-64. https://doi.org/10.1007/12_2011_150 DOI: https://doi.org/10.1007/12_2011_150

[28] D. Palmer, K. Bamsey, R. Groves, P. Patil, H. Jones, L. McAleer, P. Seaman. Printing particles: A high-throughput technique for the production of uniform, bioresorbable polymer microparticles and encapsulation of therapeutic peptides. Chemical Engineering Science 166(2017)122-129. https://doi.org/10.1016/j.ces.2017.03.038 DOI: https://doi.org/10.1016/j.ces.2017.03.038

[29] C. Gujral, Y. Minagawa, K. Fujimoto, H. Kitano, T. Nakaji-Hirabayashi. Biodegradable microparticles for strictly regulating the release of neurotrophic factors. Journal of Controlled Release 168(2013)307-316. https://doi.org/10.1016/j.jconrel.2013.03.031 DOI: https://doi.org/10.1016/j.jconrel.2013.03.031

[30] Y.W. Lim, W.S. Tan, K.L. Ho, A.R. Mariatulqabtiah, N.H. Abu Kasim, N.Abd. Rahman, T.W. Wong, C.F. Chee. Challenges and complications of poly (lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics 14(2022)614. https://doi.org/10.3390/pharmaceutics14030614 DOI: https://doi.org/10.3390/pharmaceutics14030614

[31] R.F. Pagels, R.K. Prud'Homme. Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics. Journal of Controlled Release 219(2015)519-535. https://doi.org/10.1016/j.jconrel.2015.09.001 DOI: https://doi.org/10.1016/j.jconrel.2015.09.001

[32] Y.A. Haggag, K.B. Matchett, E.H. Dakir, P. Buchanan, M.A. Osman, S.A. Elgizawy, M. El-Tanani, A.M. Faheem, P.A. McCarron. Nano-encapsulation of a novel anti-Ran-GTPase peptide for blockade of regulator of chromosome condensation 1 (RCC1) function in MDA-MB-231 breast cancer cells. International Journal of Pharmaceutics 521(2017)40-53. https://doi.org/10.1016/j.ijpharm.2017.02.006 DOI: https://doi.org/10.1016/j.ijpharm.2017.02.006

[33] E.L. Hedberg, A. Tang, R.S. Crowther, D.H. Carney, A.G. Mikos. Controlled release of an osteogenic peptide from injectable biodegradable polymeric composites. Journal of Controlled Release 84(2002)137-150. https://doi.org/10.1016/s0168-3659(02)00261-4 DOI: https://doi.org/10.1016/S0168-3659(02)00261-4

[34] J.J. Water, S. Smart, H. Franzyk, C. Foged, H.M. Nielsen. Nanoparticle-mediated delivery of the antimicrobial peptide plectasin against Staphylococcus aureus in infected epithelial cells. European Journal of Pharmaceutics and Biopharmaceutics 92(2015)65-73. https://doi.org/10.1016/j.ejpb.2015.02.009 DOI: https://doi.org/10.1016/j.ejpb.2015.02.009

[35] J. Lee, Y.J. Oh, S.K. Lee, K.Y. Lee. Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. Journal of controlled Release 146(2010)61-67. https://doi.org/10.1016/j.jconrel.2010.05.026 DOI: https://doi.org/10.1016/j.jconrel.2010.05.026

[36] X. Luan, R. Bodmeier. Modification of the tri-phasic drug release pattern of leuprolide acetate-loaded poly (lactide-co-glycolide) microparticles. European Journal of Pharmaceutics and Biopharmaceutics 63(2006)205-214. https://doi.org/10.1016/j.ejpb.2005.12.010 DOI: https://doi.org/10.1016/j.ejpb.2005.12.010

[37] B. Meng, L. Li, S. Hua, Q. Wang, C. Liu, X. Xu, X. Yin. Effect of medium-chain triglycerides on the release behavior of Endostar® encapsulated PLGA microspheres. International Journal of Pharmaceutics 397(2010)136-143. https://doi.org/10.1016/j.ijpharm.2010.07.018 DOI: https://doi.org/10.1016/j.ijpharm.2010.07.018

[38] W. Liu, A. Yang, Z. Li, H. Xu, X. Yang. PEGylated PLGA nanoparticles as tumor ecrosis factor-α receptor blocking peptide carriers: preparation, characterization and release in vitro. Journal of Wuhan University of Technology-Mater. Sci. Ed. 22(2007)112-116. https://doi.org/10.1007/s11595-005-1112-4 DOI: https://doi.org/10.1007/s11595-005-1112-4

[39] A.P.D. Santos, R.C.R.D Oliveira, B.O. Louchard, A.F.J. Uchoa, N.M.P.S Ricardo, L.K.A.M. Leal, G. Rádis-Baptista, T.G.D. Araújo. Preparation of PLGA Nanoparticles Loaded with the Anti-Infective Ctn [15-34] Peptide for Antifungal Application. Brazilian Archives of Biology and Technology 66(2023)20220775. https://doi.org/10.1590/1678-4324-2023220775 DOI: https://doi.org/10.1590/1678-4324-2023220775

[40] E.A. Gosselin, M. Noshin, S.K. Black, C.M. Jewell. Impact of excipients on stability of polymer microparticles for autoimmune therapy. Frontiers in Bioengineering and Biotechnology 8(2021)609577. https://doi.org/10.3389/fbioe.2020.609577 DOI: https://doi.org/10.3389/fbioe.2020.609577

[41] D. Rahmani, R.A. Taheri, M. Moosazadeh Moghaddam. Targeted delivery of curcumin and CM11 peptide against hepatocellular carcinoma cells based on binding affinity of PreS1-coated chitosan nanoparticles to SB3 protein. Amino Acids 57(2025)12. https://doi.org/10.1007/s00726-024-03438-x DOI: https://doi.org/10.1007/s00726-024-03438-x

[42] F. Bayat, M. Pourmadadi, M.M. Eshaghi, F. Yazdian, H. Rashedi. Improving release profile and anticancer activity of 5-fluorouracil for breast cancer therapy using a double drug delivery system: chitosan/agarose/γ-alumina nanocomposite@ double emulsion. Journal of Cluster Science 34(2023)2565-2577. https://doi.org/10.1007/s10876-023-02405-y DOI: https://doi.org/10.1007/s10876-023-02405-y

[43] B. Devrim, A. Bozkır. Preparation and in vitro evaluation of surface-modified poly (lactide-co-glycolide) microparticles as biodegradable drug carriers for pulmonary peptide and protein delivery. Journal of Microencapsulation 31(2014)355-362. https://doi.org/10.3109/02652048.2013.858791 DOI: https://doi.org/10.3109/02652048.2013.858791

[44] H.K. Büyükbayraktar, P.P. Arayıcı, M. Ihlamur, D. Gökkaya, M. Karahan, E.S. Abamor, M. Topuzoğulları. Effect of polycation coating on the long-term pulsatile release of antigenic ESAT-61–20 peptide from PLGA nanoparticles. Colloids and Surfaces B 228(2023)113421. https://doi.org/10.1016/j.colsurfb.2023.113421 DOI: https://doi.org/10.1016/j.colsurfb.2023.113421

[45] K. Michaelides, M.A. Al Tahan, Y. Zhou, G.F. Trindade, D.J. Cant, Y. Pei, P. Dulal, A. Al-Khattawi. New insights on the burst release kinetics of spray-dried PLGA microspheres. Molecular Pharmaceutics 21(2024)6245-6256. https://doi.org/10.1021/acs.molpharmaceut.4c00686 DOI: https://doi.org/10.1021/acs.molpharmaceut.4c00686

[46] C. Busatto, J. Pesoa, I. Helbling, J. Luna, D. Estenoz. Effect of particle size, polydispersity and polymer degradation on progesterone release from PLGA microparticles: Experimental and mathematical modeling. International Journal of Pharmaceutics 536(2018)360-369. https://doi.org/10.1016/j.ijpharm.2017.12.006 DOI: https://doi.org/10.1016/j.ijpharm.2017.12.006

[47] F. Khademi, A. Sahebkar, M. Fasihi‐Ramandi, R.A. Taheri. Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant. Apmis 126(2018)509-514. https://doi.org/10.1111/apm.12851 DOI: https://doi.org/10.1111/apm.12851

[48] F. Wan, M. Yang. 2016. Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying. International Journal of Pharmaceutics 498(2016)82-95. https://doi.org/10.1016/j.ijpharm.2015.12.025 DOI: https://doi.org/10.1016/j.ijpharm.2015.12.025

[49] S. Marquina, M. Ozgul, K. Robertson-Brown, M.C. Kenney. A review on PLGA particles as a sustained drug-delivery system and its effect on the retina. Experimental Eye Research 235(2023)109626. https://doi.org/10.1016/j.exer.2023.109626 DOI: https://doi.org/10.1016/j.exer.2023.109626

[50] P. Girotra, S.K. Singh, K. Nagpal. Supercritical fluid technology: a promising approach in pharmaceutical research. Pharmaceutical Development and Technology 18(2013)22-38. https://doi.org/10.3109/10837450.2012.726998 DOI: https://doi.org/10.3109/10837450.2012.726998

[51] T. Ren, X. Zheng, R. Bai, Y. Yang, L. Jian. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy. International Journal of Pharmaceutics 601(2021)120583. https://doi.org/10.1016/j.ijpharm.2021.120583 DOI: https://doi.org/10.1016/j.ijpharm.2021.120583

[52] J. Yuan, M. Guo, S. Zhao, J. Li, X. Wang, J. Yang, Z. Jin X. Song. Core-shell lipid-polymeric nanoparticles for enhanced oral bioavailability and antihypertensive efficacy of KY5 peptide. Chinese Chemical Letters 34(2023)107943. https://doi.org/10.1016/j.cclet.2022.107943 DOI: https://doi.org/10.1016/j.cclet.2022.107943

[53] H. Sun, D. Liu, Y. Li, X.. Tang, Y. Cong. Preparation and in vitro/in vivo characterization of enteric-coated nanoparticles loaded with the antihypertensive peptide VLPVPR. International Journal of Nanomedicine 9 (2014) 1709-1716. https://doi.org/10.2147/ijn.s56092 DOI: https://doi.org/10.2147/IJN.S56092

[54] Y. Wang, A. Otte, H. Park, K. Park. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly (lactide-co-glycolide). Journal of Controlled Release 377(2025)186-196. https://doi.org/10.1016/j.jconrel.2024.11.021 DOI: https://doi.org/10.1016/j.jconrel.2024.11.021

[55] R. Sharifi, M. Soloway, R.J. Correa Jr, A.G. Glass, P.D. Guinan, M.B. Garnick, L.M. Glode, J.A. Smith, B.S. Stein. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Journal of Urology 143(1990)68-71. https://doi.org/10.1016/s0022-5347(17)39868-3 DOI: https://doi.org/10.1016/S0022-5347(17)39868-3

[56] D. Modi, M.S. Hussain, S. Ainampudi, B.G. Prajapati. Long acting injectables for the treatment of prostate cancer. Journal of Drug Delivery Science and Technology 100 (2024) 105996. https://doi.org/10.1016/j.jddst.2024.105996 DOI: https://doi.org/10.1016/j.jddst.2024.105996

[57] B.L. Silverman, S. L., Blethen, E.O. Reiter, K.M. Attie, R.B. Neuwirth, K.M. Ford. A long-acting human growth hormone (Nutropin Depot®): efficacy and safety following two years of treatment in children with growth hormone deficiency. Journal of Pediatric Endocrinology and Metabolism 15(2002)715-722. https://doi.org/10.1515/jpem.2002.15.s2.715 DOI: https://doi.org/10.1515/JPEM.2002.15.S2.715

[58] I. Lancranjan, C. Bruns, P. Grass, P.Jaquet, J. Jervell, P. Kendall-Taylor, S.W.J. Lamberts, P. Marbach, H. Ørskov, G. Pagani, M. Sheppard. Sandostatin® LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45(1996)67-71. https://doi.org/10.1016/s0026-0495(96)90087-6 DOI: https://doi.org/10.1016/S0026-0495(96)90087-6

[59] L.P. Icart, F.G. Souza Jr, L.M.T. Lima. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists. Journal of Microencapsulation 38(2021)249-261. https://doi.org/10.1080/02652048.2021.1889059 DOI: https://doi.org/10.1080/02652048.2021.1889059

[60] M.C. Operti, A. Bernhardt, S. Grimm, A. Engel, C.G. Figdor, O. Tagit. PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up. International Journal of Pharmaceutics 605(2021)120807. https://doi.org/10.1016/j.ijpharm.2021.120807 DOI: https://doi.org/10.1016/j.ijpharm.2021.120807